Business Context and Reporting Period
This Form 8-K, dated March 15, 2023, reports on Graybug Vision, Inc. (the "Registrant") and its proposed merger with CalciMedica, Inc. The filing details the results of a special meeting of stockholders held on March 15, 2023, to approve the Merger Agreement entered into on November 21, 2022, and a subsequent reverse stock split.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, cash flow, or debt metrics for the reporting period. However, it discloses the following capital structure data:
- Shares Outstanding (Pre-Split): Approximately 21,997,030 shares immediately prior to the reverse stock split.
- Shares Outstanding (Post-Split): Approximately 1,571,216 shares following the split.
- Reverse Stock Split Ratio: 14-for-1.
- Trading Symbol: GRAY (Nasdaq Global Market).
- New CUSIP: 38942Q 202 (effective post-split).
Material Changes and Voting Results
Graybug stockholders voted on five proposals at the Special Meeting. All proposals were approved. The voting results based on 14,330,535 shares presented are as follows:
| Proposal | For | Against | Abstain |
|---|---|---|---|
| 1. Share Issuance & Change of Control | 13,155,174 | 1,160,128 | 15,233 |
| 2. Amended & Restated Certificate of Incorporation | 13,142,209 | 1,170,391 | 17,935 |
| 3. CalciMedica 2023 Equity Incentive Plan | 12,085,467 | 1,957,455 | 287,613 |
| 4. CalciMedica 2023 Employee Stock Purchase Plan | 13,118,277 | 943,669 | 268,589 |
| 5. Possible Adjournment of Meeting | 12,820,365 | 1,424,995 | 85,175 |
Additionally, the Board determined to effect a 14-for-1 reverse stock split effective March 17, 2023, with trading on a split-adjusted basis commencing March 20, 2023.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the expected timing and completion of the reverse stock split and the merger. Management notes that actual outcomes may differ materially due to uncertainties and risks detailed in the company's most recent Form 10-K and other SEC filings. The filing explicitly states that Graybug assumes no obligation to update these forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the final closing date of the Merger between Graybug and CalciMedica, as the filing only confirms stockholder approval.
- Confirm the exact Exchange Ratio for converting CalciMedica shares into Graybug shares, which is defined in the Merger Agreement but not explicitly stated in this text.
- Monitor the Nasdaq Global Market for the commencement of split-adjusted trading on March 20, 2023, under the new CUSIP 38942Q 202.
- Review the definitive Proxy Statement filed on February 9, 2023, for detailed terms of the equity incentive plans approved.
- Check for any cash payments in lieu of fractional shares resulting from the 14-for-1 reverse stock split.